FDA — authorised 11 January 2016
- Application: NDA208036
- Marketing authorisation holder: BRACCO
- Local brand name: E-Z-PAQUE
- Indication: FOR SUSPENSION — ORAL
- Status: approved
🇺🇸 E-Z-Hd in United States
FDA authorised E-Z-Hd on 11 January 2016
Marketing authorisations
FDA — authorised 14 October 2016
- Application: NDA208844
- Marketing authorisation holder: BRACCO
- Local brand name: VARIBAR PUDDING
- Indication: PASTE — ORAL
- Status: approved
FDA — authorised 23 January 2018
- Application: NDA208143
- Marketing authorisation holder: BRACCO
- Indication: Efficacy
- Status: approved
FDA — authorised 1 August 2025
- Application: NDA219840
- Marketing authorisation holder: BRACCO
- Indication: Type 7 - Drug Already Marketed without Approved NDA
- Status: approved
E-Z-Hd in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Gastroenterology approved in United States
Frequently asked questions
Is E-Z-Hd approved in United States?
Yes. FDA authorised it on 11 January 2016; FDA authorised it on 14 October 2016; FDA authorised it on 23 January 2018.
Who is the marketing authorisation holder for E-Z-Hd in United States?
BRACCO holds the US marketing authorisation.